SG Americas Securities LLC Raises Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

SG Americas Securities LLC lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 137.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 100,993 shares of the biopharmaceutical company's stock after acquiring an additional 58,496 shares during the quarter. SG Americas Securities LLC's holdings in Amicus Therapeutics were worth $824,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Amicus Therapeutics by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company's stock valued at $275,619,000 after buying an additional 458,143 shares during the last quarter. Wellington Management Group LLP increased its holdings in Amicus Therapeutics by 18.8% in the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company's stock valued at $268,112,000 after buying an additional 4,497,950 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in Amicus Therapeutics by 4.4% in the fourth quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company's stock valued at $35,866,000 after buying an additional 159,139 shares during the last quarter. Northern Trust Corp increased its holdings in Amicus Therapeutics by 5.9% in the fourth quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company's stock valued at $31,761,000 after buying an additional 187,652 shares during the last quarter. Finally, Vestal Point Capital LP purchased a new position in Amicus Therapeutics in the fourth quarter valued at $31,557,000.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on FOLD shares. The Goldman Sachs Group dropped their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, UBS Group upped their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Amicus Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $16.22.

Amicus Therapeutics Stock Performance

NASDAQ FOLD traded up $0.07 during trading hours on Monday, hitting $5.71. 5,706,513 shares of the stock were exchanged, compared to its average volume of 3,090,951. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -63.44 and a beta of 0.54. Amicus Therapeutics, Inc. has a 12-month low of $5.59 and a 12-month high of $12.65. The stock has a 50-day moving average of $6.37 and a 200 day moving average of $8.13. The company has a quick ratio of 2.47, a current ratio of 3.34 and a debt-to-equity ratio of 2.02.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.